eso - going nowhere and another indication that vis works on a limited list of cancers. pancreatic - the italian study was ok, but not overwhelming. we knew that vis is promising with stem cells in pancreatic adeno cancer. it is interesting that i have never heard another word that i can remember regarding vis and "cutting off the fuel supply" (glutamine). still nothing about vis/gem/abraxane in pancreatic; phii primary was due in december.
this is of interest to me: "Abraxane/Gemcitabine Combination Improves Survival of Pancreatic Cancer Patients" (von hoff). we already knew that a nda was going to be submitted. of special interest is this line: " Significantly there was no increase in life-threatening toxicity. Other drug combinations that have demonstrated benefit have been limited by increased toxicities." does this mean the triple? maybe, maybe not.